Triiodothyronine (T3) suppresses hepatic tumorigenesis and development by inhibiting the phosphorylation of ERK

Abstract

AbstractThe effect of triiodothyronine (T3) on the phosphorylation of ERK and the occurrence and development of hepatocellular carcinoma (HCC) is controversial and remains to be clarified. In the present study, both in vitro (hepatoma cell lines) and in vivo (wild‐type mice [WT] and mouse models of HCC [HrasG12Vand KrasG12Dtransgenic mice (Hras‐Tg and Kras‐Tg)]) systems were used to investigate the effect of T3 on p‐ERK and hepatocarcinogenesis. The results showed that, in vitro, T3 treatment elevated the levels of p‐ERK in hepatoma cells within 30 min. However, p‐ERK levels returned to normal after 1 h with no significant effects on cellular proliferation or apoptosis. Interestingly, in vivo, T3 induced early rapid and transient activation of ERK and later persistent downregulation of p‐ERK in liver tissues of WT. In Hras‐Tg, liver weight, liver/body weight ratio, hepatic tumor numbers and sizes were significantly reduced withT3treatment compared with the untreated group. Furthermore, the levels of albumin, HrasG12V, and p‐ERK in hepatic precancerous and tumor tissues were all significantly downregulated with T3 treatment; however, the levels of endogenous Hras were not affected. In WT, T3 also induced downregulation of Albumin in liver tissues, but without influence on the expression of endogenous Hras and p‐MEK. Especially, the inhibitory effect of T3 on p‐ERK and hepatic tumorigenesis and development without influence on the levels of KrasG12D and p‐MEK was further confirmed in Kras‐Tg. In conclusion, T3 suppresses hepatic tumorigenesis and development by independently and substantially inhibiting the phosphorylation of ERK in vivo.